The evolution of epigenetic therapy in myelodysplastic syndromes and acute myeloid leukemia

被引：6

作者：

Gonzalez-Lugo, Jesus D. ^{[1
]}

Chakraborty, Samarpana ^{[1
,2
]}

Verma, Amit ^{[1
,2
]}

Shastri, Aditi ^{[1
,2
]}

机构：

[1] Montefiore Med Ctr, Albert Einstein Coll Med, Div Hematol Malignancies, Dept Oncol, Moses Campus,111 East 210th St,Hofheimer 100, Bronx, NY 10467 USA

[2] Albert Einstein Coll Med, Dept Mol & Dev Biol, Bronx, NY 10467 USA

来源：

SEMINARS IN HEMATOLOGY | 2021年 / 58卷 / 01期

关键词：

D O I：

10.1053/j.seminhematol.2020.12.003

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Mutations in the group of epigenetic modifiers are the largest group of mutated genes in Myelodysplastic Syndromes (MDS) and are very frequently found in Acute Myeloid Leukemia (AML). Our advancements in the understanding of epigenetics in these diseases have helped develop groundbreaking therapeutics that have changed the treatment landscape of MDS and AML, significantly improving outcomes. In this review we describe the most common epigenetic aberrations in MDS and AML, and current treatments that target mutations in epigenetic modifiers, as well as novel treatment combinations, from standard therapies to investigational treatments. (C) 2021 Elsevier Inc. All rights reserved.

引用

页码：56 / 65

页数：10

共 125 条

[91] Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes [J].

Sallman, D. A. ;

Komrokji, R. ;

Vaupel, C. ;

Cluzeau, T. ;

Geyer, S. M. ;

McGraw, K. L. ;

Al Ali, N. H. ;

Lancet, J. ;

McGinniss, M. J. ;

Nahas, S. ;

Smith, A. E. ;

Kulasekararaj, A. ;

Mufti, G. ;

List, A. ;

Hall, J. ;

Padron, E. .

LEUKEMIA, 2016, 30 (03) :666-673

[92] Phase 2 Results of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML) [J].

Sallman, David A. ;

DeZern, Amy E. ;

Garcia-Manero, Guillermo ;

Steensma, David P. ;

Roboz, Gail J. ;

Sekeres, Mikkael A. ;

Cluzeau, Thomas ;

Sweet, Kendra L. ;

McLemore, Amy F. ;

McGraw, Kathy ;

Puskas, John ;

Zhang, Ling ;

Yao, Jiqiang ;

Mo, Qianxing ;

Nardelli, Lisa ;

Al Ali, Najla ;

Padron, Eric ;

Korbel, Greg ;

Attar, Eyal C. ;

Kantarjian, Hagop M. ;

Lancet, Jeffrey E. ;

Fenaux, Pierre ;

List, Alan F. ;

Komrokji, Rami S. .

BLOOD, 2019, 134

[93] Clonal Suppression of TP53 Mutant MDS and Oligoblastic AML with Hypomethylating Agent Therapy Improves Overall Survival [J].

Sallman, David A. ;

Al Ali, Najla ;

Yun, Seongseok ;

Padron, Eric ;

Song, Jinming ;

Hussaini, Mohammad Omar ;

Talati, Chetasi ;

Sweet, Kendra L. ;

Lancet, Jeffrey E. ;

List, Alan F. ;

Komrokji, Rami S. .

BLOOD, 2018, 132

[94]

Sallman DA, 2020, J CLIN ONCOL, V38

[95] An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study [J].

Savona, Michael R. ;

Odenike, Olatoyosi ;

Amrein, Philip C. ;

Steensma, David P. ;

DeZern, Amy E. ;

Michaelis, Laura C. ;

Faderl, Stefan ;

Harb, Wael ;

Kantarjian, Hagop ;

Lowder, James ;

Oganesian, Aram ;

Azab, Mohammad ;

Garcia-Manero, Guillermo .

LANCET HAEMATOLOGY, 2019, 6 (04) :E194-E203

[96] Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia [J].

Schenk, Tino ;

Chen, Weihsu Claire ;

Goellner, Stefanie ;

Howell, Louise ;

Jin, Liqing ;

Hebestreit, Katja ;

Klein, Hans-Ulrich ;

Popescu, Andreea C. ;

Burnett, Alan ;

Mills, Ken ;

Casero, Robert A., Jr. ;

Marton, Laurence ;

Woster, Patrick ;

Minden, Mark D. ;

Dugas, Martin ;

Wang, Jean C. Y. ;

Dick, John E. ;

Mueller-Tidow, Carsten ;

Petrie, Kevin ;

Zelent, Arthur .

NATURE MEDICINE, 2012, 18 (04) :605-611

[97] Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117 [J].

Sekeres, Mikkael A. ;

Othus, Megan ;

List, Alan F. ;

Odenike, Olatoyosi ;

Stone, Richard M. ;

Gore, Steven D. ;

Litzow, Mark R. ;

Buckstein, Rena ;

Fang, Min ;

Roulston, Diane ;

Bloomfield, Clara D. ;

Moseley, Anna ;

Nazha, Aziz ;

Zhang, Yanming ;

Velasco, Mario R. ;

Gaur, Rakesh ;

Atallah, Ehab ;

Attar, Eyal C. ;

Cook, Elina K. ;

Cull, Alyssa H. ;

Rauh, Michael J. ;

Appelbaum, Frederick R. ;

Erba, Harry P. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (24) :2745-+

[98] Stem and progenitor cell alterations in myelodysplastic syndromes [J].

Shastri, Aditi ;

Will, Britta ;

Steidl, Ulrich ;

Verma, Amit .

BLOOD, 2017, 129 (12) :1586-1594

[99] Combined Targeting of JAK2 with a Type II JAK2 Inhibitor and mTOR with a TOR Kinase Inhibitor Constitutes Synthetic Activity in JAK2-Driven Ph-like Acute Lymphoblastic Leukemia [J].

Shi, Ce ;

Han, Lina ;

Zhang, Qi ;

Roberts, Kathryn G. ;

Park, Eugene ;

Tabe, Yoko ;

Jacamo, Rodrigo Omar ;

Mu, Hong ;

Wu, Shuo-Chieh ;

Zhou, Jin ;

Ma, Helen ;

Zeng, Zhihong ;

Jain, Nitin ;

Jabbour, Elias J. ;

Muschen, Markus ;

Tasian, Sarah K. ;

Mullighan, Charles G. ;

Weinstock, David M. ;

Fruman, David ;

Konopleva, Marina .

BLOOD, 2015, 126 (23)

[100] Histone demethylation mediated by the nuclear arnine oxidase homolog LSD1 [J].

Shi, YJ ;

Lan, F ;

Matson, C ;

Mulligan, P ;

Whetstine, JR ;

Cole, PA ;

Casero, RA ;

Shi, Y .

CELL, 2004, 119 (07) :941-953

← 4 5 6 7 8 9 10 11 12 13 →